Surgery Partners Inc (SGRY)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $3.53B
Last updated: Nov 17, 2026 at 11:06 AM ET
Surgery Partners Inc (SGRY) Financials: Revenue, Profit and Cash Flow
Surgery Partners reported revenue of $3.31B for the fiscal year ended Dec 31, 2025, up 6.2% from the year before. That year, net income was $98.90M with a net margin of 3.0%, operating cash flow was $274.30M and free cash flow was $195.60M. The quarter ended Sep 30, 2026 had revenue of $815.30M and net income of $14.10M.
Revenue and Margins
The operating margin was 11.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.15B, a compound annual rate of 12.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3.31B | +6.2% | 70.7% | 11.8% | 3.0% |
| Dec 2024 | $3.11B | +13.5% | 38.3% | 11.2% | 0.4% |
| Dec 2023 | $2.74B | +8.0% | 37.5% | 12.0% | 4.9% |
| Dec 2022 | $2.54B | +14.1% | 42.7% | 13.6% | 3.4% |
| Dec 2021 | $2.23B | +19.6% | 42.4% | 13.6% | 3.2% |
| Dec 2020 | $1.86B | +1.6% | 41.5% | 9.8% | 0.1% |
| Dec 2019 | $1.83B | +3.4% | 42.2% | 12.9% | 2.5% |
| Dec 2018 | $1.77B | +32.1% | 28.0% | 4.4% | -5.4% |
| Dec 2017 | $1.34B | +17.1% | 24.4% | 11.8% | -4.0% |
| Dec 2016 | $1.15B | N/A | 28.3% | 17.2% | 7.4% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 691.2% from the year before. In the quarter ended Sep 2026, net income fell 44.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.31B | $3.11B | $2.74B | $2.54B | $2.23B | $1.86B | $1.83B | $1.77B | $1.34B | $1.15B |
| Cost of revenue | $971.00M | $1.92B | $1.71B | $1.46B | $1.28B | $1.09B | $1.06B | $1.27B | $1.01B | $821.20M |
| Gross profit | $2.34B | $1.19B | $1.03B | $1.08B | $944.40M | $771.40M | $773.50M | $496.80M | $327.42M | $324.24M |
| Operating income | $389.50M | $348.80M | $328.00M | $345.20M | $302.20M | $183.00M | $235.90M | $77.80M | $158.23M | $196.48M |
| Net income | $98.90M | $12.50M | $135.30M | $87.00M | $70.70M | $1.30M | $45.10M | -$95.60M | -$52.98M | $85.08M |
| EBITDA | $565.50M | $501.40M | $446.10M | $460.00M | $401.00M | $277.80M | $310.00M | $145.20M | $251.88M | $232.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $815.30M | $848.90M | $810.90M | $885.00M | $821.50M | $826.20M | $776.00M | $864.40M | $770.40M | $762.10M | $717.40M | $735.40M |
| Gross profit | $308.00M | $595.80M | $563.50M | $1.06B | $369.80M | $376.00M | $278.00M | $346.70M | $292.40M | $293.80M | $259.30M | -$152.30M |
| Operating income | $85.60M | $102.10M | $65.80M | $110.20M | $105.70M | $111.70M | $61.90M | $127.10M | $60.90M | $84.80M | $76.00M | $101.40M |
| Net income | $14.10M | $29.70M | -$2.10M | $29.00M | $25.30M | $44.90M | -$300.00K | -$46.60M | $6.40M | $28.40M | $24.30M | $46.70M |
Balance Sheet
As of Dec 2025, total debt of $3.70B exceeded cash and equivalents by $3.46B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $8.12B | $7.89B | $6.88B | $6.68B | $6.12B | $5.41B | $5.02B | $4.68B | $4.62B | $2.30B |
| Current assets | $1.15B | $1.12B | $895.00M | $921.00M | $946.10M | $801.50M | $525.50M | $588.30M | $563.23M | $361.95M |
| Cash and equivalents | $239.90M | $269.50M | $195.90M | $282.90M | $389.90M | $317.90M | $92.70M | $184.30M | $174.91M | $69.70M |
| Total liabilities | $4.59B | $4.25B | $3.51B | $3.40B | $3.82B | $3.79B | $3.32B | $2.89B | $2.66B | $1.80B |
| Short-term debt | $99.30M | $101.40M | $73.30M | $62.80M | $60.40M | $64.40M | $56.00M | $55.60M | $58.73M | $27.82M |
| Long-term debt | $3.60B | $3.27B | $2.70B | $2.56B | $2.88B | $2.79B | $2.52B | $2.27B | $2.13B | $1.41B |
| Shareholder equity | $1.71B | $1.79B | $1.99B | $2.00B | $1.09B | $115.60M | $296.80M | $404.60M | $654.73M | $9.68M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.05B | $8.05B | $8.04B | $8.24B | $7.95B | $7.95B | $7.95B | $7.89B | $7.53B | $7.49B | $6.98B | $6.88B |
| Total liabilities | $3.79B | $4.58B | $4.56B | $4.72B | $4.39B | $4.38B | $4.36B | $4.25B | $3.99B | $3.87B | $3.61B | $3.51B |
| Cash and equivalents | $354.50M | $216.70M | $182.30M | $239.90M | $203.40M | $250.10M | $229.30M | $269.50M | $221.80M | $213.50M | $185.20M | $195.90M |
| Shareholder equity | $1.66B | $1.67B | $1.69B | $1.71B | $1.73B | $1.75B | $1.74B | $1.79B | $1.90B | $1.95B | $1.97B | $1.99B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 71.3% of operating cash flow. Dividends came to 115.2% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $274.30M | $300.10M | $293.80M | $158.80M | $87.10M | $246.90M | $129.50M | $144.60M | $120.94M | $125.24M |
| Capital expenditures | $78.70M | $90.40M | $88.80M | $80.60M | $57.60M | $42.90M | $73.60M | $39.80M | $29.60M | $39.11M |
| Free cash flow | $195.60M | $209.70M | $205.00M | $78.20M | $29.50M | $204.00M | $55.90M | $104.80M | $91.34M | $86.13M |
| Dividends paid | $225.40M | $160.90M | $137.90M | $150.20M | $164.50M | $137.00M | $124.40M | $119.00M | $1.32M | $85.87M |
| Share repurchases | N/A | N/A | N/A | $25.20M | $27.60M | $0 | $0 | $2.00M | N/A | $0 |
| Investing cash flow | -$246.60M | -$488.50M | -$225.60M | -$307.90M | -$331.70M | -$88.40M | -$85.20M | -$128.90M | -$783.45M | -$184.75M |
| Financing cash flow | -$57.30M | $262.00M | -$155.20M | $42.10M | $316.30M | $66.70M | -$135.90M | -$6.30M | $767.72M | $71.28M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $103.50M | $59.30M | $11.70M | $103.40M | $83.60M | $81.30M | $6.00M | $111.40M | $65.20M | $82.80M | $40.70M | $62.60M |
| Capital expenditures | $24.50M | $21.80M | $16.00M | $12.80M | $19.80M | $23.40M | $22.70M | $22.30M | $20.20M | $26.90M | $21.00M | $19.80M |
| Free cash flow | $79.00M | $37.50M | -$4.30M | $90.60M | $63.80M | $57.90M | -$16.70M | $89.10M | $45.00M | $55.90M | $19.70M | $42.80M |
Frequently Asked Questions About SGRY
What is Surgery Partners' annual revenue?
Surgery Partners reported revenue of $3.31B for the fiscal year ended Dec 31, 2025.
How fast is Surgery Partners' revenue growing?
Revenue was up 6.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 9.2%.
Is Surgery Partners profitable?
Yes. Surgery Partners reported net income of $98.90M for the fiscal year ended Dec 31, 2025, with a net margin of 3.0%.
How much free cash flow does SGRY generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $274.30M minus capital expenditures of $78.70M produced free cash flow of $195.60M.
How much debt does Surgery Partners have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $3.60B, short-term debt of $99.30M and cash and equivalents of $239.90M.
SGRY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors